Biovian is looking forward to participating in the BIO International Convention on June 13th-16th in San Diego. #BIO2022 is back in person. Biovian representatives, CBO Magnus Gustafsson and Head of Business Development Eero Mustalahti are …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
Biovian’s client satisfaction survey was conducted in November using Net Promoter Score (NPS) survey. The score of 67 puts Biovian into the category “Excellent” based on the creators of NPS, Bain & Co. Flexibility, good …
New Horizons 2021 event took place on December 9th in Stockholm. Dr. Magnus Gustafsson from Biovian gave a talk about “Gene therapy today and tomorrow.” New Horizons is an international educational forum that focuses on …
Biovian received a new automated filling line right before Christmas in 2020 from Optima packaging group. This article describes the project from the planning phase until the assembly of the filling line. The project is …
Biovian and Lokon Pharma are featured in Biopharma Dealmakers September issue. The article “Manufacturing the next generation of cancer immunotherapeutics”, describes the history and currents state of Lokon Pharma’s proprietary LOAd technology. This immunostimulatory gene …
GEN, one of the biggest magazines in the field of genetic engineering and biotechnology, discussed with four experts how the relationship between a CDMO and a technology provider can accelerate the transition from academia to …
The leading regional newspaper of of the Southwest Finland interviewed Knut Ringbom, the CEO of Biovian about the COVID-19 vaccine manufacturing possibilities. “Pandemic vaccine manufacturing is a hot topic. We have been contacted by European …
GEN, one of the biggest biotech magazines interviewed Biovian about the critical bottlenecks in Adeno-associated virus (AAV) Manufacturing. AAVs, gene therapy and manufacturing technologies are two of the “hottest” biotech areas in the industry right …
Adeno-associated virus (AAV) has emerged as the most flexible and useful vector for gene therapy. With hundreds of gene therapy trials ongoing, safe and efficient production of AAV is absolutely critical. In this roundtable discussion, …
